Stichting Health Action International

EU Legislative Interests

HAI advocates for policy initiatives that help to address current shortfalls/shortcomings in access to medicines. In Europe, HAI monitors EU policy initiatives and developments that have an impact on access to medicines, their rational use and on the democratization of medicines policy. We also work on exposing major risks that the use of Artificial Intelligence (AI) in healthcare can cause, including discrimination, harming citizens health and safety, and the exacerbation of health inequalities, which infringes on patients’ fundamental rights. Where needed, we issue recommendations for improvement on specific topics. EU legislation, policies and initiatives of particular interest include: implementation of proposals on clinical trials regulation; discussion of European Pharmaceutical Strategy and review of EU pharmaceutical legislation, and other IP incentives, including the Proposal for a regulation of the European Parliament and of the Council on compulsory licensing for crisis management; European Union IP Action Plan and enforcement strategy, including revision of Supplementary Protection Certificate Regulation; Competition policy; EU trade agreements with impact on access to medicines; Innovative Medicines Initiative and Horizon Europe; implementation of the One Health Action Plan against AMR; new and current European Medicine Agency (EMA)'s policies and activities, including tackling medicines shortages.

Communication Activities

For our publications please visit: https://haiweb.org/publication/ For our press releases and other news please visit: https://haiweb.org/news/ In 2025, we published more than 15 reports, briefings and consultation responses and hosted a number of events and meetings to discuss and disseminate these. These publications formed the basis of our advocacy work. In the same period, our European project work and staff and members were quoted or mentioned in the media at least 45 times, demonstrating the added value of our published materials and that our staff are seen by media contacts as experts in their field. The European Projects Team has worked closely with the HAI Communications Team to develop engaging content that promoted our work and helped achieve project objectives. We re-worked TRIPS Flexibilities Navigator to improve its useability and reach, with a brand new look. This living resource designed to help to educate lawmakers, policymakers, researchers, and the public about how the use of TRIPS Flexibilities as a legitimate tool to improve access to patented medicines has received excellent feedback from users.

Interests Represented

Does not represent commercial interests

Member Of

HAI is a member of the European Public Health Alliance (EPHA), the International Society of Drug Bulletins (ISDB), the Transatlantic Consumer Dialogue (TACD), the Medicines in Europe Forum (MiEF), the European Alliance for Responsible R&D and Affordable Medicines, the Antimicrobial Resistance Coalition (ARC), and Global Snakebite Initiative. At the national level HAI is member of the Dutch Global Health Alliance (DGHA) and the Medicijnen Netwerk. In addition, HAI enters into strategic partnership with other associations when collaborating on certain topics thus tapping into extended expertise as required. HAI is in official relations with the WHO and collaborates with the organization on several projects as well as attending governing bodies and ad-hoc meetings. Others: EU Pharmaceutical Strategy IP Package Framework Program 10 HERA work plan EU guidelines and National Action Plans of Member States on Anti-Microbial Resistance European Health- Data Space and the EMA / HMA Big Data Workplan The EU Artificial Intelligence Act The EU Medical Devices Regulation GDPR

Organisation Members

BUKO Pharma-Kampagne Public Eye La Revue Prescrire Medico International Medicus Mundi Switzerland Mezis Oxfam GB Salud por Derecho Wemos T1 International Health Projects for Latvia EKPIZO UAEM Partnership for Global Health /plan:g The Independent Diabetes Trust (IDDT)

Additional Information

N/A